VAL201 Update

RNS Number : 6621D

ValiRx PLC

01 April 2014

 

01 April 2014

ValiRx Plc

("ValiRx" or "the Company")

VAL201 Update

Further to the announcement on 24 October 2013, ValiRx Plc (AIM: VAL), the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, provides an update on its leading anti-cancer therapeutic, VAL201, following the meeting a week ago of the compound's Clinical Trial Project Team ("CTPT").

The CTPT includes the principal investigator at University College Hospital, London, who will oversee patient recruitment and will conduct the trial, and the Medical Monitoring Officer, in association with all relevant manufacturing monitoring, regulatory and compliance personnel.

The Company is informed by the CTPT that it could proceed now, but the CTPT have recommended that a further stability and sterility study be completed to further strengthen the compound's data package and permit the future rapid progress towards a phase 2 efficacy study.

This follows the earlier acceleration of the study, as previously announced, to commence direct human trials in cancer patients at the Phase Ib stage.

 The Company has accepted the advice of the CTPT and the further work is underway and will complete shortly with preliminary positive outcomes and results, which are now being integrated into the regulatory and technical data package.

The Company anticipates that it will be in a position to use the expanded regulatory documentation shortly and believes that this strategic decision, supported by the CTPT, will create the most effective outcome and value.

- ENDS -

For more information, please contact:

ValiRx plc	Tel: [phone]
Dr Satu Vainikka	www.valirx.com
Cairn Financial Advisers LLP (Nominated Adviser)	Tel: [phone]
Liam Murray / Avi Robinson
Daniel Stewart & Company Plc (Broker)	Tel: [phone]
David Hart
Peckwater PR	Tel: [phone]
Tarquin Edwards	[e-mail]

Notes for Editors

ValiRx Plc

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Company operates through the following divisional companies:

1. ValiFinn is the biomarkers and diagnostic development division

2. ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers.

 

END

 

 

MSCSDFESFFLSEED